Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
In the register
The register attaches this trial to DA-001 / DA-002 / DA-005 (Applied Biology), currently at “Phase 1/2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Not yet recruiting
- Declared phase
- Phase 2/3
- Sponsor
- Applied Biology, Inc.
- Participants (registry)
- 1120
- Start
- May 2026 (planned)
- Primary completion
- March 2027 (planned)
- Study completion
- April 2027 (planned)
- Last registry update
- April 2026
- Countries
- —
Conditions studied: Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia, Male Pattern Baldness, Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Interventions: DA-001, Placebo, Phenylephrine, DA-001 Topical + DA-005 Oral (HIF-1α supplement), DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement), Phenylephrine Topical 0.25% + Intact Pro Topical, Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)
Other trials of DA-001 / DA-002 / DA-005
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
Pharmacokinetic Study of DA-020
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia
Pharmacokinetic Study of Topical Phenylephrine
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.